The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting

BACKGROUND: Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose combination (FDC) of two active antiemetic agents in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaswani, Bharat, Dattatreya, Palanki Satya, Bhagat, Sagar, Patil, Saiprasad, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145828/
https://www.ncbi.nlm.nih.gov/pubmed/34034703
http://dx.doi.org/10.1186/s12885-021-08342-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145828/
https://www.ncbi.nlm.nih.gov/pubmed/34034703
http://dx.doi.org/10.1186/s12885-021-08342-1

Ejemplares similares